Clinical Trials Logo

Filter by:
NCT ID: NCT02290275 Completed - Clinical trials for Osteoarthritis, Knee

Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis

Start date: January 2015
Phase: N/A
Study type: Interventional

The goal of this research project is to determine the effectiveness of creatine supplementation and supported low-load walking exercise for managing systemic inflammatory biomarkers and joint symptoms in individuals diagnosed with chronic symptomatic knee osteoarthritis. The central hypothesis of this investigation is that creatine supplementation and exercise will significantly lower systemic biomarkers of inflammation in patients diagnosed with knee osteoarthritis.

NCT ID: NCT02289898 Completed - Pancreatic Cancer Clinical Trials

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

YOSEMITE
Start date: April 20, 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT02289716 Completed - Pain Clinical Trials

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

Start date: July 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.

NCT ID: NCT02289690 Completed - Clinical trials for Small Cell Lung Cancer

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Start date: October 13, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).

NCT ID: NCT02289612 Completed - Clinical trials for Type 2 Diabetes Mellitus

Glycemic and Satiety Response Study of Fibre-Enriched Pudding Products

Pudding
Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the specific properties of a variety of dietary fibres that lead to different postprandial glycemic and satiety responses in individuals at risk for type 2 diabetes. This is accomplished by utilizing a variety of dietary fibres that demonstrate a wide range of properties in a pudding product, and by examining the ability of each of these to limit gastric emptying, limit glucose absorption, limit insulin secretion, and improve satiety, versus a low fibre control product.

NCT ID: NCT02289417 Completed - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

UC
Start date: January 8, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).

NCT ID: NCT02288884 Completed - Clinical trials for Surgical Wound Infection

The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section

Start date: May 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of a silver containing dressing (Acticoat Post-Op) compared to a standard dressing (OpSite PostOp) on post elective cesarean section wound complications in obese women (BMI >35).

NCT ID: NCT02287662 Completed - Clinical trials for Aortic Valve Stenosis

The Multidisciplinary, Multimodality, But Minimalist Approach to Transfemoral Transcatheter Aortic Valve Replacement

3MTAVR
Start date: March 2015
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the efficacy, safety and feasibility of next day discharge home in patients undergoing balloon-expandable transfemoral TAVR utilizing the Vancouver 3M Clinical Pathway in low, medium, and high volume North American centres.

NCT ID: NCT02286596 Completed - Clinical trials for Homozygous Familial Hypercholesterolemia

Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia

APHERESE
Start date: April 2013
Phase: N/A
Study type: Observational

Homozygous familial hypercholesterolemia (HoFH) is characterized by a six- to eight-fold raise in plasma LDL-cholesterol (LDL-C) concentrations and atherosclerotic coronary artery disease usually occur before the age of 20 if untreated. Lipid apheresis (LA) has been proved to be a reliable method to decrease LDL-C concentrations and therefore decrease cardiovascular disease risk in HoFH. The objective of this crossover study was to compare efficacy of LA performed with heparin-induced extracorporeal LDL precipitation to dextran sulfate adsorption on the reduction of lipids, inflammatory markers, adhesion molecules and LDL particles size in a cohort of HoFH subjects.

NCT ID: NCT02286219 Completed - Clinical trials for Solid Tumors That Overexpress HER2 (HER2 Positive)

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Start date: November 4, 2014
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, dose limiting toxicity (DLT), and maximum tolerated dose (MTD), of FS102(BMS-986186) when administered intravenously (IV) to subjects with relapsed or refractory solid tumors that overexpress HER2 and who have no standard treatment options.